Recent studies reported increased plasma glial acidic fibrillary protein (GFAP) levels in amyotrophic lateral sclerosis (ALS) patients compared to controls. We expanded these findings in a larger cohort, including 156 ALS patients and 48 controls, and investigated the associations of plasma GFAP with clinical variables and other biofluid biomarkers. Plasma GFAP and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers were assessed by the single molecule array and the Lumipulse platforms, respectively. In ALS patients, plasma GFAP was higher than in controls (p < 0.001) and associated with measures of cognitive decline. Twenty ALS patients (12.8%) showed a positive amyloid status (A+), of which nine also exhibited tau pathology (A+T+, namely ALS-AD). ALS-AD patients showed higher plasma GFAP than A- ALS participants (p < 0.001) and controls (p < 0.001), whereas the comparison between A- ALS and controls missed statistical significance (p = 0.07). Plasma GFAP distinguished ALS-AD subjects more accurately (area under the curve (AUC) 0.932 & PLUSMN; 0.027) than plasma p-tau181 (AUC 0.692 & PLUSMN; 0.058, p < 0.0001) and plasma neurofilament light chain protein (AUC, 0.548 & PLUSMN; 0.088, p < 0.0001). Cognitive measures differed between ALS-AD and other ALS patients. AD co-pathology deeply affects plasma GFAP values in ALS patients. Plasma GFAP is an accurate biomarker for identifying AD co-pathology in ALS, which can influence the cognitive phenotype.

Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis / Mastrangelo, Andrea; Vacchiano, Veria; Zenesini, Corrado; Ruggeri, Edoardo; Baiardi, Simone; Cherici, Arianna; Avoni, Patrizia; Polischi, Barbara; Santoro, Francesca; Capellari, Sabina; Liguori, Rocco; Parchi, Piero. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 24:18(2023), pp. 13976.1-13976.15. [10.3390/ijms241813976]

Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis

Mastrangelo, Andrea;Vacchiano, Veria;Baiardi, Simone;Avoni, Patrizia;Capellari, Sabina;Liguori, Rocco;Parchi, Piero
2023

Abstract

Recent studies reported increased plasma glial acidic fibrillary protein (GFAP) levels in amyotrophic lateral sclerosis (ALS) patients compared to controls. We expanded these findings in a larger cohort, including 156 ALS patients and 48 controls, and investigated the associations of plasma GFAP with clinical variables and other biofluid biomarkers. Plasma GFAP and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers were assessed by the single molecule array and the Lumipulse platforms, respectively. In ALS patients, plasma GFAP was higher than in controls (p < 0.001) and associated with measures of cognitive decline. Twenty ALS patients (12.8%) showed a positive amyloid status (A+), of which nine also exhibited tau pathology (A+T+, namely ALS-AD). ALS-AD patients showed higher plasma GFAP than A- ALS participants (p < 0.001) and controls (p < 0.001), whereas the comparison between A- ALS and controls missed statistical significance (p = 0.07). Plasma GFAP distinguished ALS-AD subjects more accurately (area under the curve (AUC) 0.932 & PLUSMN; 0.027) than plasma p-tau181 (AUC 0.692 & PLUSMN; 0.058, p < 0.0001) and plasma neurofilament light chain protein (AUC, 0.548 & PLUSMN; 0.088, p < 0.0001). Cognitive measures differed between ALS-AD and other ALS patients. AD co-pathology deeply affects plasma GFAP values in ALS patients. Plasma GFAP is an accurate biomarker for identifying AD co-pathology in ALS, which can influence the cognitive phenotype.
2023
Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis / Mastrangelo, Andrea; Vacchiano, Veria; Zenesini, Corrado; Ruggeri, Edoardo; Baiardi, Simone; Cherici, Arianna; Avoni, Patrizia; Polischi, Barbara; Santoro, Francesca; Capellari, Sabina; Liguori, Rocco; Parchi, Piero. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 24:18(2023), pp. 13976.1-13976.15. [10.3390/ijms241813976]
Mastrangelo, Andrea; Vacchiano, Veria; Zenesini, Corrado; Ruggeri, Edoardo; Baiardi, Simone; Cherici, Arianna; Avoni, Patrizia; Polischi, Barbara; Santoro, Francesca; Capellari, Sabina; Liguori, Rocco; Parchi, Piero
File in questo prodotto:
File Dimensione Formato  
ijms-24-13976.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 747.18 kB
Formato Adobe PDF
747.18 kB Adobe PDF Visualizza/Apri
ijms-24-13976-s001.zip

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 112.78 kB
Formato Zip File
112.78 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/961174
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact